Cancer Research UK, Abcodia to develop blood Dx attuned to early-stage cancers

Cancer Research UK, by way of its commercial division known as Cancer Research Technology, will collaborate with Abcodia on new blood tests designed to spot cancers at very early stages. Their work will focus, in part, on identifying biomarkers that will let clinicians detect cancer before patients even have symptoms. And they'll try to fill a diagnostic gap, focusing on cancers for which many screening tests aren't widely in use. Item

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.